Perspective Therapeutics, Inc. (CATX) is a publicly traded company in the Healthcare — Medical - Devices industry listed on AMEX. This overview shows the latest price, key valuation ratios, profitability metrics and financial-health indicators used by fundamental investors.
Perspective Therapeutics, Inc., including its various operations, specializes in the comprehensive lifecycle – from development and manufacturing to sales and marketing – of radiopharmaceutical products and medical devices. These advanced solutions are designed to treat cancer and other serious malignant conditions, serving markets both within the United States and globally. A flagship product offered by the company is its CS-1 Cesium-131 brachytherapy seeds.
Analysis Summary
Trailing-twelve-month margins: gross margin -419.4%, operating margin -342.2%, net margin -318.1%.
At the current price of $2.88, CATX has negative trailing earnings (P/E not meaningful) and an ROE of -41.56%. Market capitalisation stands at $328M.
Balance sheet quality for CATX: current ratio of 5.2, net cash position of $141.5M. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Price
| Price | $2.88 |
| Market Cap | $328M |
| Exchange | AMEX |
| Country | US |
Valuation Ratios
| Price / Book | 0.55 |
| EV / EBITDA | -2.37 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -41.56% |
| Return on Invested Capital | -34.94% |
| Return on Assets | -29.70% |
| Gross Margin | -419.40% |
| Operating Margin | -34216.39% |
| Net Margin | -31812.57% |
Financial Health
| Debt / Equity | 0.01 |
| Current Ratio | 6.61 |
What to look at in Healthcare / Pharma
The R&D pipeline is the invisible asset. Patents expiring = revenues evaporating. Look at innovation and cash flow.
- R&D / Revenue — Shows investment in future pipeline. Serious pharma reinvests 15-20%
- 5y EPS growth — After patent expirations, are they still growing?
- Gross margin — Branded pharma >70%. Generics much lower — defines the business type
- FCF / Net Income — Earnings quality — big pharma should convert >90%
- ROIC — Capital reinvested efficiently — key in pharma due to long R&D cycles
- Net debt / EBITDA — Pharma acquisitions pile up debt — watch the post-M&A picture
- P/E vs own 10y history — The best comparison is with its own history, not with peers
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| CATX | Perspective Therapeutics, Inc. | $308M | 0.55 | -41.6% | |
| ABT | Abbott Laboratories | $177.1B | 32.49 | 3.45 | 10.5% |
| 0Y6X.L | Medtronic Plc | $125.7B | |||
| MDT | Medtronic plc | $118.5B | 22.97 | 2.39 | 10.6% |
| SYK | Stryker Corporation | $109.2B | 29.95 | 4.66 | 16.4% |
| 0R2S.L | Stryker Corporation | $107.9B | 29.27 | 4.55 | 16.4% |
| 0HOY.L | Boston Scientific Corporation | $66.5B | 48.91 | 5.86 | 11.9% |
| BSX | Boston Scientific Corporation | $65.3B | 17.73 | 2.61 | 14.9% |
Price Performance
| 1 month | -15.89% |
| 3 months | -8.47% |
| Year-to-date | -1.82% |
| 1 year | -11.18% |
| 3 years | -15.62% |
52-Week Range
| 52-week High | $6.16 |
| 52-week Low | $1.96 |
| Avg Volume (90d) | 1.5M |
Related companies: AVR · ELMD · HSDT · IVVD · MXCT · NNOX · NYXH
Explore sector: Healthcare · Medical - Devices
More sections of CATX: Financials · Valuation · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks